Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 11
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 11

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderDyadic · 57
Strongest available pathCardiff Oncology · -86.5%
Widest latest marginDyadic · -238.3%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DYAI · Nasdaq

Dyadic

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1979Jupiter, Florida$24.6M market cap
View full Companies Radar profile
57Moderate
Snapshot price$0.61as of page date
Monthly-close return-89.9%five-year window
FY2025 revenue$0.00BDYADIC INTERNATIONAL INC
Net margin-238.3%FY2025
Prism attention30.8%share across these five
Filing track recordRevenue, USD billions
+28.6%
$0$0.0B$0.0B$0.0BFY2021: $0.002BFY2022: $0.003BFY2023: $0.003BFY2024: $0.003BFY2025: $0.003B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 6.5%
52-week position1% through range
$0.60$1.60
News mentions909
Community mentions0partial coverage
U.S.-scope patents133
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal83/100
Management stability90/100
Market position6/100
Capital-event signal80/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 4 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ALGS · Nasdaq

Aligos Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2018San Francisco, California$43.1M market cap
View full Companies Radar profile
51Moderate
Snapshot price$6.91as of page date
Monthly-close return-98.3%five-year window
FY2025 revenue$0.00BAligos Therapeutics, Inc.
Net margin-1106.7%FY2025
P/E snapshot-1.4xone ratio, not a verdict
Prism attention21.0%share across these five
Filing track recordRevenue, USD billions
-64.7%
$0$0.0B$0.0B$0.0BFY2023: $0.006BFY2024: $0.004BFY2025: $0.002B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -40.6%
52-week position30% through range
$3.98$13.69
News mentions620
Community mentions7partial coverage
U.S.-scope patents503
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal75/100
Management stability90/100
Market position21/100
Capital-event signal44/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BCAB · Nasdaq

BioAtla

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2010San Diego, California$2.9M market cap
View full Companies Radar profile
40Cautious
Snapshot price$1.74as of page date
Monthly-close return-99.8%five-year window
FY2022 revenue$0.00BBioAtla, Inc.
Net margin-35494.0%FY2022
Prism attention16.6%share across these five
Filing track recordRevenue, USD billions
+0.0%
$0$0.0B$0.0B$0.0BFY2021: $0.000BFY2022: $0.000B20212022
FY2021–FY2022 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.0%
52-week position0% through range
$1.51$71.50
News mentions490
Community mentions10partial coverage
U.S.-scope patents702
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal38/100
Management stability90/100
Market position0/100
Capital-event signal65/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4IMA · Nasdaq

Ikena Oncology

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016Boston$60.6M market cap
View full Companies Radar profile
40Cautious
Snapshot price$5.34as of page date
Monthly-close return-96.5%five-year window
FY2025 revenue$0.00BImageneBio, Inc.
Net margin-5668.6%FY2025
P/E snapshot-1.2xone ratio, not a verdict
Prism attention9.9%share across these five
Filing track recordRevenue, USD billions
-97.4%
$0$0.0B$0.0B$0.0BFY2021: $0.031BFY2022: $0.016BFY2023: $0.009BFY2024: $0.009BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -59.9%
52-week position14% through range
$3.94$13.98
News mentions293
Community mentions4partial coverage
U.S.-scope patents201
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal52/100
Management stability90/100
Market position9/100
Capital-event signal37/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CRDF · Nasdaq

Cardiff Oncology

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1999San Diego, California$73.1M market cap
View full Companies Radar profile
31Cautious
Snapshot price$0.94as of page date
Monthly-close return-86.5%five-year window
FY2025 revenue$0.00BCardiff Oncology, Inc.
Net margin-7732.0%FY2025
P/E snapshot-1.6xone ratio, not a verdict
Prism attention21.7%share across these five
Filing track recordRevenue, USD billions
+65.2%
$0$0.0B$0.0B$0.0BFY2021: $0.000BFY2022: $0.000BFY2023: $0.000BFY2024: $0.001BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.4%
52-week position7% through range
$0.76$3.31
News mentions641
Community mentions0partial coverage
U.S.-scope patents79
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position0/100
Capital-event signal38/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Cardiff Oncology
-86.5%
Dyadic
-89.9%
Ikena Oncology
-96.5%
Aligos Therapeutics
-98.3%
BioAtla
-99.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Dyadic
$0.00B
Aligos Therapeutics
$0.00B
Ikena Oncology
$0.00B
Cardiff Oncology
$0.00B
BioAtla
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Dyadic
-238.3%
Aligos Therapeutics
-1106.7%
Ikena Oncology
-5668.6%
Cardiff Oncology
-7732.0%
BioAtla
-35494.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Dyadic
30.8%
Cardiff Oncology
21.7%
Aligos Therapeutics
21.0%
BioAtla
16.6%
Ikena Oncology
9.9%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Dyadic leads the conversation

It holds 30.8% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Cardiff Oncology leads the available price paths

Its monthly-close return is -86.5% for the five-year window. At the other end, BioAtla is -99.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Dyadic has the widest latest margin

Its FY2025 net margin is -238.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cardiff Oncology shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -1.6x while its five-year window price return is -86.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DYAI

Dyadic

909available Prism news records

Prism top themes

Earnings & financial performance
20
Price action & investor response
12
Leadership & governance
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.8%110 latest 12m vs 102 prior 12m
2024-01: 9 mentions2024-02: 15 mentions2024-03: 17 mentions2024-04: 4 mentions2024-05: 11 mentions2024-06: 11 mentions2024-07: 11 mentions2024-08: 4 mentions2024-09: 5 mentions2024-10: 5 mentions2024-11: 9 mentions2024-12: 0 mentions2025-01: 6 mentions2025-02: 43 mentions2025-03: 11 mentions2025-04: 3 mentions2025-05: 3 mentions2025-06: 2 mentions2025-07: 7 mentions2025-08: 11 mentions2025-09: 3 mentions2025-10: 16 mentions2025-11: 13 mentions2025-12: 9 mentions2026-01: 8 mentions2026-02: 9 mentions2026-03: 16 mentions2026-04: 8 mentions2026-05: 9 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

89.1% positive-2.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine formulation 13diagnostic biotechnology 11subunit vaccines 11synthetic biology 10viral vector vaccines 10enzyme engineering 9mrna vaccines 8stock performance 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-12 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DYAI

Dyadic

through 2025-08-05
Earnings releases 5Company announcements 1Listing / IPO 1
  1. Earnings releases

    Dyadic International, Inc. (Nasdaq: DYAI) ... today announced that it will report its financial results for the second quarter 2025.

  2. Listing / IPO

    Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share.

  3. Company announcements

    In March 2024, the company released its financial results for the fiscal year 2023, with the company reporting revenues of $2,899,000

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ALGS

Aligos Therapeutics

through 2026-04-17
Earnings releases 31Company announcements 6Leadership changes 4Business contracts 1
  1. Business contracts

    Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.

  2. Earnings releases

    Based on Aligos Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $741 thousand and a GAAP net loss of $31.54 million.

  3. Company announcements

    Shares of Aligos Therapeutics Inc. (NASDAQ:ALGS) were trading at $10.70, down $3.46, or 24%, after the South San Francisco-based firm disclosed top‑line results from the phase IIa Herald study of ALG‑055009, a thyroid hormone receptor beta agonist, in metabolic‑dysfunction associated steatohepatitis (MASH) subjects.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BCAB

BioAtla

through 2026-03-31
Earnings releases 8Company announcements 3Lawsuits 1
  1. Company announcements

    today announced that it will effect a 50-for-1 share consolidation (the “Share Consolidation”) of its common stock, par value $0.0001 per share (the “Common Stock”), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the “Effective Date”).

  2. Earnings releases

    For the full year 2025, net loss was $59.6 million , compared to $69.8 million for the full year 2024.

  3. Lawsuits

    Kaskela Law LLC announces that it has commenced a shareholder investigation into BioAtla, Inc. (NASDAQ:BCAB) on behalf of the company's investors.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IMA

Ikena Oncology

through 2025-07-25
Earnings releases 8M&A 4
  1. M&A

    today announced the completion of its previously announced merger with Ikena Oncology, Inc.

  2. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ikena Oncology $659,000.00 82.75 -$68.17 million ($1.01) -1.12

  3. M&A

    Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) and Inmagene Biopharmaceuticals (“Inmagene”) announced they have entered into a definitive merger agreement.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CRDF

Cardiff Oncology

through 2026-02-01
Earnings releases 4Leadership changes 3
  1. Leadership changes

    Cardiff’s CEO Mark Erlander, PhD, and CFO James Levine have stepped down, with Erlander succeeded by an interim CEO, Mani Mohindru, PhD, a member of Cardiff’s board since 2021.

  2. Earnings releases

    Cardiff Oncology, Inc. (CRDF) on Thursday reported a loss of $13.4 million in its first quarter.

  3. Leadership changes

    Cardiff has promoted Brigitte Lindsay, a 14-year Cardiff veteran who had been senior vice president of finance, to the role of chief accounting officer—a move the company said will ensure continuity within its finance operations.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 51–58. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Dyadic and Dyadic

Dyadic has the largest displayed latest revenue at $0.00B; Dyadic has the widest displayed latest margin at -238.3%.

Open Dyadic in Companies Radar
Comparisons
Anomalies

Cardiff Oncology has the widest attention-readiness rank gap

It ranks #2 by measured news attention (21.7%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Cardiff Oncology in Companies Radar

Cardiff Oncology shows a price-operating divergence to inspect

Its displayed filing-revenue change is +65.2% while its available monthly-close return is -86.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Cardiff Oncology in Companies Radar
Explanations

Attention measures coverage volume, not quality

Dyadic's 30.8% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Dyadic in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Dyadic's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 57/100 score.

Open Dyadic in Companies Radar

Stress-test the largest divergence before forming a view

Compare Cardiff Oncology's profile with Cardiff Oncology's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Cardiff Oncology in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon